Tengion Launches Second Phase 2 Clinical Trial Of Regenerated Human Organ
Tengion, Inc., a leader in regenerative medicine, announced it has initiated a Phase 2 multi-center clinical trial of its neo-bladder construct, derived from a patient’s own cells. The U.S.-based study is being conducted in 10 adult patients with neurogenic bladder due to spinal cord injuries. Neurogenic bladder is a condition that can occur due to spinal cord injury and may lead to kidney failure and incontinence, even when patients receive optimal medical treatment. [click link for full article]
More: continued here
Filed under: Stem Cell Research on September 20th, 2007